CY1118016T1 - ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣ - Google Patents
ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣInfo
- Publication number
- CY1118016T1 CY1118016T1 CY20161100905T CY161100905T CY1118016T1 CY 1118016 T1 CY1118016 T1 CY 1118016T1 CY 20161100905 T CY20161100905 T CY 20161100905T CY 161100905 T CY161100905 T CY 161100905T CY 1118016 T1 CY1118016 T1 CY 1118016T1
- Authority
- CY
- Cyprus
- Prior art keywords
- acetyl
- pyrazolosepiroketone
- inhibitions
- coa carboxyl
- coa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Η εφεύρεση παρέχει ένωση του Τύπου (I) Ζ Ν Ν Ο Ν Ο Α1R2 R1 R3R 3 L Α 2 (I) ή φαρμακευτικώς αποδεκτό άλας της ένωσης, όπου R1, R2, R3, Ζ, Α1, L και Α2 είναι όπως περιγράφεται στο παρόν· φαρμακευτικές συνθέσεις αυτής· και τη χρήση αυτής στη θεραπεία ασθενειών, καταστάσεων ή διαταραχών που ρυθμίζονται με την αναστολή ενός ενζύμου(-ων) ακετυλ-CoA καρβοξυλάσης σε ένα ζώο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38810210P | 2010-09-30 | 2010-09-30 | |
PCT/IB2011/054119 WO2012042433A1 (en) | 2010-09-30 | 2011-09-20 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118016T1 true CY1118016T1 (el) | 2017-05-17 |
Family
ID=44789556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100905T CY1118016T1 (el) | 2010-09-30 | 2016-09-13 | ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣ |
Country Status (15)
Country | Link |
---|---|
US (8) | US8859577B2 (el) |
EP (1) | EP2621493B1 (el) |
JP (1) | JP5824055B2 (el) |
CA (1) | CA2811033C (el) |
CY (1) | CY1118016T1 (el) |
DK (1) | DK2621493T3 (el) |
ES (1) | ES2602111T3 (el) |
HR (1) | HRP20161178T1 (el) |
HU (1) | HUE031616T2 (el) |
LT (1) | LT2621493T (el) |
PL (1) | PL2621493T3 (el) |
PT (1) | PT2621493T (el) |
RS (1) | RS55224B1 (el) |
SI (1) | SI2621493T1 (el) |
WO (1) | WO2012042433A1 (el) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040198483A1 (en) | 2003-04-03 | 2004-10-07 | Amaitis Lee M. | System and method for betting on a subset of participants in an event |
US8636571B2 (en) | 2004-02-03 | 2014-01-28 | Cantor Index, Llc | System and method for managing select five horseracing bets |
US9098883B2 (en) | 2004-02-03 | 2015-08-04 | Cantor Index, Llc | Managing bets that select events and participants |
WO2009144554A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Pyrazolospiroketone acetyl-c0a carboxylase inhibitors |
ES2444543T3 (es) | 2009-11-10 | 2014-02-25 | Pfizer Inc | Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa |
PT2621493T (pt) | 2010-09-30 | 2016-11-14 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
CN103189377B (zh) | 2010-10-29 | 2015-02-25 | 辉瑞大药厂 | N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂 |
PT2699576E (pt) * | 2011-04-22 | 2016-03-09 | Pfizer | Derivados de pirazoloespirocetona para utilização como inibidores de acetil-coa carboxilase |
CA2863365A1 (en) | 2012-01-30 | 2013-08-08 | Cfph, Llc | Event wagering with group and/or in run options |
US11055967B2 (en) | 2014-03-26 | 2021-07-06 | Cfph, Llc | Event wagering with group and/or in run options |
US20170178994A1 (en) * | 2015-12-21 | 2017-06-22 | Intel Corporation | Integrated circuit package support structures |
KR102579876B1 (ko) | 2016-02-22 | 2023-09-18 | 삼성전자주식회사 | 반도체 패키지 |
EP3612175A1 (en) * | 2017-04-18 | 2020-02-26 | Genfit | Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent |
EP3713942B8 (en) * | 2017-11-21 | 2023-04-12 | Pfizer Inc. | Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid |
US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
AU2019329884B2 (en) * | 2018-08-31 | 2022-01-27 | Pfizer Inc. | Combinations for treatment of NASH/NAFLD and related diseases |
US20220387402A1 (en) | 2019-05-20 | 2022-12-08 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
CN110183456A (zh) * | 2019-07-11 | 2019-08-30 | 河南师范大学 | 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法 |
CN115175893A (zh) | 2019-12-10 | 2022-10-11 | 辉瑞公司 | 2-((4-((S)-2-(5-氯吡啶-2-基)-2-甲基苯并[d][1,3]二氧杂环戊烯-4-基)哌啶-1-基)甲基)-1-(((S)-氧杂环丁烷-2-基)甲基)-1H-苯并[d]咪唑-6-甲酸, 1,3-二羟基-2-(羟基甲基)丙烷-2-胺盐的固体形式 |
JP2023509452A (ja) | 2020-01-03 | 2023-03-08 | バーグ エルエルシー | がんを処置するためのube2kモジュレータとしての多環式アミド |
JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Nafld/nashおよび関連疾患の処置のための組合せ |
JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
IL296694A (en) | 2020-03-27 | 2022-11-01 | Pfizer | Treatment of type 2 diabetes, obesity or excess weight using 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[( 2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or its pharmaceutical salts |
BR112024002129A2 (pt) | 2021-08-31 | 2024-04-30 | Pfizer | Formas sólidas de ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico, sal de 1,3-di-hidróxi-2-(hidroximetil)propan-2-amina |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2287971T3 (es) | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
IL157253A0 (en) | 2001-02-28 | 2004-02-19 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
DE60301491T2 (de) | 2002-02-27 | 2006-05-18 | Pfizer Products Inc., Groton | Acc-hemmer |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
WO2004092179A1 (ja) | 2003-04-14 | 2004-10-28 | Nippon Soda Co. Ltd. | スピロ誘導体、製造法および抗酸化薬 |
JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
WO2005113069A2 (en) | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of circumin and analogues as inhibitors of acc2 |
GEP20094723B (en) | 2004-05-25 | 2009-07-10 | Pfizer Prod Inc | Tetraazabenzo [e] azulene derivatives and analogs thereof |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
ATE509023T1 (de) | 2005-07-19 | 2011-05-15 | Merck Sharp & Dohme | Spirochromanon-derivate als acetyl-koenzym-a- carboxylase-hemmer |
JPWO2007013691A1 (ja) | 2005-07-29 | 2009-02-12 | 武田薬品工業株式会社 | スピロ環化合物 |
DE102006016566B4 (de) | 2005-09-22 | 2008-06-12 | Beru Ag | Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren |
EP1951251B1 (en) | 2005-11-18 | 2010-12-29 | Merck Sharp & Dohme Corp. | Spirohydantoin aryl cgrp receptor antagonists |
CN101384568B (zh) | 2006-02-15 | 2012-12-12 | 雅培制药有限公司 | 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
MX2009005604A (es) | 2006-11-29 | 2009-06-08 | Pfizer Prod Inc | Inhibidores espiro cetona de acetil-coa carboxilasa. |
WO2008088692A2 (en) * | 2007-01-12 | 2008-07-24 | Merck & Co., Inc. | Spirochromanon derivatives |
PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
JPWO2008102749A1 (ja) | 2007-02-20 | 2010-05-27 | 武田薬品工業株式会社 | 複素環化合物 |
CA2683695C (en) | 2007-04-12 | 2013-06-18 | Pfizer Inc. | 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives |
US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
WO2009144554A1 (en) * | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Pyrazolospiroketone acetyl-c0a carboxylase inhibitors |
JP2011521940A (ja) | 2008-05-28 | 2011-07-28 | ファイザー・インク | ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤 |
US8524730B2 (en) * | 2008-07-04 | 2013-09-03 | Msd K.K. | Spirochromanone carboxylic acids |
AU2009271634A1 (en) | 2008-07-14 | 2010-01-21 | Cropsolution, Inc. | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
ES2444543T3 (es) | 2009-11-10 | 2014-02-25 | Pfizer Inc | Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa |
CA2778316A1 (en) * | 2009-11-10 | 2011-05-19 | Pfizer Inc. | N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors |
PT2621493T (pt) * | 2010-09-30 | 2016-11-14 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
US20160034775A1 (en) | 2014-08-02 | 2016-02-04 | General Vault, LLC | Methods and apparatus for bounded image data analysis and notification mechanism |
-
2011
- 2011-09-20 PT PT117681635T patent/PT2621493T/pt unknown
- 2011-09-20 LT LTEP11768163.5T patent/LT2621493T/lt unknown
- 2011-09-20 US US13/876,211 patent/US8859577B2/en active Active
- 2011-09-20 JP JP2013530829A patent/JP5824055B2/ja active Active
- 2011-09-20 RS RS20160845A patent/RS55224B1/sr unknown
- 2011-09-20 DK DK11768163.5T patent/DK2621493T3/en active
- 2011-09-20 HU HUE11768163A patent/HUE031616T2/hu unknown
- 2011-09-20 ES ES11768163.5T patent/ES2602111T3/es active Active
- 2011-09-20 WO PCT/IB2011/054119 patent/WO2012042433A1/en active Application Filing
- 2011-09-20 EP EP11768163.5A patent/EP2621493B1/en active Active
- 2011-09-20 PL PL11768163T patent/PL2621493T3/pl unknown
- 2011-09-20 SI SI201130951A patent/SI2621493T1/sl unknown
- 2011-09-20 CA CA2811033A patent/CA2811033C/en active Active
-
2014
- 2014-09-19 US US14/491,016 patent/US9145416B2/en active Active
-
2015
- 2015-09-11 US US14/851,572 patent/US20150376185A1/en not_active Abandoned
-
2016
- 2016-08-15 US US15/236,635 patent/US9908883B2/en active Active
- 2016-09-13 CY CY20161100905T patent/CY1118016T1/el unknown
- 2016-09-14 HR HRP20161178TT patent/HRP20161178T1/hr unknown
-
2018
- 2018-01-30 US US15/883,109 patent/US10294225B2/en active Active
-
2019
- 2019-04-01 US US16/371,896 patent/US10822335B2/en active Active
-
2020
- 2020-09-28 US US17/034,295 patent/US11673890B2/en active Active
-
2023
- 2023-05-03 US US18/311,715 patent/US20230322777A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
HRP20161178T1 (hr) | 2016-11-04 |
CA2811033A1 (en) | 2012-04-05 |
US20180162858A1 (en) | 2018-06-14 |
US20160347752A1 (en) | 2016-12-01 |
US10822335B2 (en) | 2020-11-03 |
SI2621493T1 (sl) | 2016-10-28 |
PL2621493T3 (pl) | 2017-01-31 |
US20150011470A1 (en) | 2015-01-08 |
RS55224B1 (sr) | 2017-02-28 |
JP2013540119A (ja) | 2013-10-31 |
US20130190334A1 (en) | 2013-07-25 |
HUE031616T2 (hu) | 2017-07-28 |
DK2621493T3 (en) | 2016-10-24 |
US20210047325A1 (en) | 2021-02-18 |
US20150376185A1 (en) | 2015-12-31 |
US9145416B2 (en) | 2015-09-29 |
ES2602111T3 (es) | 2017-02-17 |
CA2811033C (en) | 2015-10-20 |
WO2012042433A1 (en) | 2012-04-05 |
US9908883B2 (en) | 2018-03-06 |
US11673890B2 (en) | 2023-06-13 |
PT2621493T (pt) | 2016-11-14 |
JP5824055B2 (ja) | 2015-11-25 |
US10294225B2 (en) | 2019-05-21 |
US8859577B2 (en) | 2014-10-14 |
US20190218218A1 (en) | 2019-07-18 |
LT2621493T (lt) | 2016-10-25 |
EP2621493A1 (en) | 2013-08-07 |
EP2621493B1 (en) | 2016-08-17 |
US20230322777A1 (en) | 2023-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118016T1 (el) | ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣ | |
CY1116405T1 (el) | Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης | |
CY1117122T1 (el) | Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης | |
CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
NI201200089A (es) | INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA. | |
CY1120104T1 (el) | Αναστολεις της syk | |
CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
CY1121549T1 (el) | Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων | |
CY1119361T1 (el) | 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις | |
CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
UY36056A (es) | “compuestos de heteroarilo o arilo bicíclicos fusionados “. | |
CY1124243T1 (el) | Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1 | |
CY1122182T1 (el) | Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες | |
CY1120881T1 (el) | Ανταγωνιστες υποδοχεα 5-ητ3 | |
CY1121137T1 (el) | Φαρμακευτικα σκευασματα που περιλαμβανουν ανταγωνιστες ccr3 | |
CY1122613T1 (el) | Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139 | |
EA201490491A1 (ru) | Производные 2-амино-4-(пиридин-2-ил)-5,6-дигидро-4h-1,3-оксазинов и их использование в качестве ингибиторов bace-1 и/или bace-2 | |
ECSP13012788A (es) | Derivados de biciclo[3,2,1]octilamida y sus usos | |
CY1116168T1 (el) | Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 | |
PH12016500480B1 (en) | Antibacterial 2h-indazole derivatives | |
BR112015029348A2 (pt) | inibidores da bace | |
TR201900393T4 (tr) | 1,2-Dihidro-3H-Pirolo[1,2-C]İmidazol-3-On Türevleri Ve Bunların Antibakteriyel Ajanlar Olarak Kullanımı | |
CY1115800T1 (el) | Παραγωγα της 3-(ετεροαρυλο-αμινο)-1,2,3,4-τετραϋδρo-9η-καρβαζολης και η χρηση τους ως ρυθμιστες των υποδοχεων της προσταγλανδινης d2 | |
CY1111701T1 (el) | Υδροχλωρικο αλας του 5-[3-(3-υδροξυφαινοξυ)αζετιδιν-1-υλ]-5-μεθυλ-2,2-διφαινυλεξαναμιδιου | |
CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa |